Chengdu Huasun Group Inc Ltd (000790) fair value: what the stock is really worth
We calculate from audited financials what Chengdu Huasun Group Inc Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Chengdu Huasun Group Inc Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ¥3.09 – ¥7.21 · fair‑value band ¥0.4700 – ¥0.8400 · the ¥3.99 price screens above the ¥0.6400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 13, 2026.
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs.
Show more
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs, as well as medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company designs, produces, installs, and services steel structure buildings. The company was formerly known as Chengdu Taihe Health Technology Group Inc., Ltd. and changed its name to Chengdu huasun technology group Inc. , LTD. in April 2020. The company was founded in 1988 and is based in Chengdu, China.
Stock analysis
Chengdu Huasun Group Inc Ltd (000790) currently trades at ¥3.99, while our model-based Fair Value estimate is ¥0.6400, implying the stock looks roughly 523.4% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥0.7700 per share, and 0 of the 7 models we run sit above the ¥3.99 price.
Bear case: the Multiples group reads lowest at ¥0.6000, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.4700 (bear) to ¥0.8400 (bull), the price of ¥3.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Chengdu Huasun Group Inc Ltd reported revenue of 545M CNY in FY2025 versus 955M CNY in FY2021, a compound −13.1%/yr. Reported net income was −320M CNY in FY2025.
Key figures
Market cap 2.5B CNY (≈ $371M) · P/S ratio 4.31 · EPS (TTM) ¥−0.4800 · Dividend yield 0.6% · Net margin −58.7% · Return on equity −37.6% · Return on assets (EBIT) 0.4% · Operating margin 5.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 17% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −84%, 000790 screens richer than that median.
Fair Value models
Bear ¥0.4700Fair Value ¥0.6400Bull ¥0.8400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue growth is weak, negative or inconsistent.
Latest YoY
−36.9%
Revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.5%
Revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Revenue growth/yr (30Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Share of sales kept as operating profit (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.2% (2020) → −17.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, ten years of growth, then 2 % a year. Compared with the average analyst sales forecast (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.3%
How much the company would have to grow every year for ten years to justify the current price.
Analysts expect (Ø )
n/a
No analyst forecast available.
🔴 A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Profitability
Return on assets−3% · Bottom 25%
Net margin (TTM)−57% · Bottom 25%
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth−14% · Bottom 25%
Dividend yield (TTM)0.6% · Below median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.47× · Cheapest 25%
P/S (TTM)0.64× · Cheapest 25%
P/FCF15.2× · Priciest 25%
PEG1.67× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 13
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 25
HEALTH (low debt)97· sector 97
DIVIDEND (yield)12· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Chengdu Huasun Group Inc Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000790
Frequently asked questions
Is Chengdu Huasun Group Inc Ltd (000790) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥0.6400 versus a price of ¥3.99, about −84% upside (overvalued).
What is the fair value of 000790?
Our model-based fair value for Chengdu Huasun Group Inc Ltd is ¥0.6400 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥3.99.
What is the quality score of 000790?
Chengdu Huasun Group Inc Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chengdu Huasun Group Inc Ltd (000790)?
Our model-based price target is the fair value of ¥0.6400 (as of Sep 13, 2026) from 7 valuation models. Cautious scenario ¥0.4700, optimistic scenario ¥0.8400. It is a calculation from audited fundamentals, not an analyst target.
What is the Chengdu Huasun Group Inc Ltd stock forecast for 2026?
Our models put fair value at ¥0.6400, about −84% upside versus a price of ¥3.99 (overvalued). Cautious scenario ¥0.4700, optimistic scenario ¥0.8400. The calculation is refreshed regularly with new filings.
What is the revenue of Chengdu Huasun Group Inc Ltd (000790)?
Chengdu Huasun Group Inc Ltd reported trailing-twelve-month revenue of about 528M CNY (latest available figure, as of Sep 13, 2026).
Does Chengdu Huasun Group Inc Ltd pay a dividend?
Chengdu Huasun Group Inc Ltd currently shows a dividend yield of about 0.58% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Chengdu Huasun Group Inc Ltd (000790)?
For today's price to be fair in a discounted-cash-flow model, Chengdu Huasun Group Inc Ltd would have to grow free cash flow by +33.3 % per year for ten years (discount rate 10.4 %, then 2 % perpetual growth). Over the last 5 years revenue grew -6.4 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 000790 use?
Our models discount Chengdu Huasun Group Inc Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.21, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chengdu Huasun Group Inc Ltd that is +33.3 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Chengdu Huasun Group Inc Ltd (000790) delivered so far?
Over the past 5 years revenue at Chengdu Huasun Group Inc Ltd grew -6.4 % a year. The price currently implies +33.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chengdu Huasun Group Inc Ltd (000790) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Chengdu Huasun Group Inc Ltd (+33.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chengdu Huasun Group Inc Ltd (000790)?
The free-cash-flow yield on the price is 0.90 %: that much free cash flow Chengdu Huasun Group Inc Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chengdu Huasun Group Inc Ltd (000790)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chengdu Huasun Group Inc Ltd it is ¥0.6400 per share (as of Sep 13, 2026), against a price of ¥3.99. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Chengdu Huasun Group Inc Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 000790 trades above its calculated fair value: price ¥3.99, fair value ¥0.6400, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000790?
No. The price is what the market pays today (¥3.99); the fair value is what the company's own numbers justify (¥0.6400). For Chengdu Huasun Group Inc Ltd the two are ¥3.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chengdu Huasun Group Inc Ltd worth?
The market values Chengdu Huasun Group Inc Ltd at about 2.5B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥3.99; our models calculate a fair value of ¥0.6400 per share.
What do the bullish and bearish scenarios say about 000790?
Our models span a range for Chengdu Huasun Group Inc Ltd: cautious scenario ¥0.4700, base ¥0.6400, optimistic ¥0.8400 per share (as of Sep 13, 2026, price ¥3.99). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 000790?
The PEG ratio of Chengdu Huasun Group Inc Ltd is 1.67 (P/E divided by earnings growth, as of Sep 13, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Chengdu Huasun Group Inc Ltd (000790)?
Balance-sheet figures for Chengdu Huasun Group Inc Ltd (as of Sep 13, 2026): return on equity −37.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 000790 from its 52-week high?
Chengdu Huasun Group Inc Ltd trades at ¥3.99, about 17% below its 52-week high of ¥4.79 and 12% above the low of ¥3.55 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.6400 is for.
Which stocks are comparable to Chengdu Huasun Group Inc Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chengdu Huasun Group Inc Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price ¥3.99, calculated fair value ¥0.6400 (−84%), Quality Score 46/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000790 calculated?
We run Chengdu Huasun Group Inc Ltd through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.6400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.0 % above its aggregate fair value. Chengdu Huasun Group Inc Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Chengdu Huasun Group Inc Ltd right now?
The price sits above even our optimistic bull case (¥0.8400). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Chengdu Huasun Group Inc Ltd (000790) come from?
Earnings per share at Chengdu Huasun Group Inc Ltd grew −6.0 % a year from 2013 to 2024. Broken into its drivers: revenue per share +4.8 %, EBIT margin −5.2 %, tax rate +1.3 %, residual (interest, one-offs) −6.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Chengdu Huasun Group Inc Ltd
How large is the market capitalisation of Chengdu Huasun Group Inc Ltd (000790)?
The market capitalisation of Chengdu Huasun Group Inc Ltd is 2.5B CNY (≈ $371M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chengdu Huasun Group Inc Ltd (000790)?
The price-to-sales ratio of Chengdu Huasun Group Inc Ltd is 4.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chengdu Huasun Group Inc Ltd (000790)?
Earnings per share at Chengdu Huasun Group Inc Ltd are ¥−0.4800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chengdu Huasun Group Inc Ltd (000790)?
The dividend yield of Chengdu Huasun Group Inc Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chengdu Huasun Group Inc Ltd (000790)?
The net margin of Chengdu Huasun Group Inc Ltd is −58.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chengdu Huasun Group Inc Ltd (000790)?
The return on equity (ROE) of Chengdu Huasun Group Inc Ltd is −37.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chengdu Huasun Group Inc Ltd (000790)?
On an EBIT basis the return on assets of Chengdu Huasun Group Inc Ltd is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chengdu Huasun Group Inc Ltd (000790)?
The operating margin of Chengdu Huasun Group Inc Ltd is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chengdu Huasun Group Inc Ltd (000790)?
Revenue at Chengdu Huasun Group Inc Ltd is growing −13.9% versus a year earlier (3y avg −14.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chengdu Huasun Group Inc Ltd (000790)?
Earnings per share at Chengdu Huasun Group Inc Ltd are growing −40.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Chengdu Huasun Group Inc Ltd (000790) carry?
The net debt of Chengdu Huasun Group Inc Ltd is 104M CNY (fiscal year 2025, ≈ 4.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Chengdu Huasun Group Inc Ltd in the live analysis
One click puts Chengdu Huasun Group Inc Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
